Video
New Longer-term Efficacy, Safety Data of Asciminib in CML
Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.
Pharmacy Times interviewed Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, on her presentation at the 63rd American Society of Hematology Annual Meeting & Exposition on new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study for FDA-approved asciminib.
During the interview, Mendila discussed the results of the phase 3 ASCEMBL study and the longer-term efficacy and safety data of asciminib in the treatment of chronic myeloid leukemia.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
